Twist Bioscience’s (TWST) “Buy” Rating Reiterated at TD Cowen

TD Cowen reaffirmed their buy rating on shares of Twist Bioscience (NASDAQ:TWST) in a report released on Tuesday,Benzinga reports. The firm currently has a $58.00 price target on the stock.

A number of other research analysts have also recently commented on TWST. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Scotiabank increased their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Twist Bioscience Trading Up 4.3 %

TWST stock opened at $48.32 on Tuesday. Twist Bioscience has a 1-year low of $23.07 and a 1-year high of $60.90. The company’s 50 day moving average is $43.78 and its 200 day moving average is $46.22. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -13.42 and a beta of 1.78.

Insider Buying and Selling

In related news, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the sale, the insider now owns 91,163 shares of the company’s stock, valued at $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the transaction, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at $3,068,728.57. This represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 over the last quarter. 3.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in TWST. American International Group Inc. lifted its position in Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after buying an additional 213 shares during the period. PEAK6 Investments LLC lifted its position in Twist Bioscience by 20.7% during the first quarter. PEAK6 Investments LLC now owns 14,000 shares of the company’s stock valued at $480,000 after buying an additional 2,400 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after buying an additional 2,292 shares during the period. Silvercrest Asset Management Group LLC raised its position in shares of Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the last quarter. Finally, Bayesian Capital Management LP raised its position in shares of Twist Bioscience by 42.7% in the 1st quarter. Bayesian Capital Management LP now owns 14,546 shares of the company’s stock worth $499,000 after purchasing an additional 4,352 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.